GW Pharmaceuticals plc

GW Pharmaceuticals — Technical Presentation (December 2017)

24 slides from GW Pharmaceuticals's technical presentation, Dec 4, 2017

  1. Slide 1: History of Cannabidiol (CBD) and GW Clinical Trial Program

    History of Cannabidiol (CBD) and GW Clinical Trial Program 1899 CBN from cannabis resin (Wood et al) 1969 CBD synthesis absolute configuration (Petrzilka et al) 1981 Test CBD as anticonvulsant in humans (Petro et al) 1988 Specific THC- binding sites (cannabinoid receptor type, CB1) in the rat brain

  2. Slide 2: Ongoing GWPCARE Phase 3 Trials

    Ongoing GWPCARE Phase 3 Trials INTRODUCTION The GWPCARE phase 3 clinical trial program, sponsored by GW Research Ltd, includes 7 studies evaluating the safety and efficacy of a pharmaceutical formulation of purified cannabidiol (CBD; Epidiolex®) across 4 drug-resistant epilepsy indications: GWPCARE1

  3. Slide 3: GW/Greenwich Pipeline Indications Under Investigation

    GW/Greenwich Pipeline Indications Under Investigation PRECLINICAL PHASE 1 PHASE 2 PHASE 3 SUBMIT APPROAL Epidiolex® (cannabidiol)* A Dravet Syndrome B Lennox-Gastaut Syndrome C Tuberous Sclerosis D Infantile Spasms (Pilot Phase) Other Pipeline Candidates Epilepsy Autism Spectrum Disorders Neonatal H

  4. Slide 4: The Burden of Illness of Dravet Syndrome in the United States

    The Burden of Illness of Dravet Syndrome in the United States Michael Chez1 | Anup Patel2 | Susan E. Funk3 | Tyler J. Story4 Nancy L. Reaven3 1Sutter Medical Group, Sacramento, CA, USA; 2Nationwide Children’s Hospital, Columbus, OH, USA; 3Strategic Health Resources, La Cañada, CA, USA; 4Greenwich Bi

  5. Slide 5: The Burden of Illness of Lennox-Gastaut Syndrome

    The Burden of Illness of Lennox-Gastaut Syndrome Georgia Montouris1 | Susan E. Funk2 | Timothy B. Saurer3 | Tyler J. Story3 Nancy L. Reaven2 1Department of Neurology, Boston University School of Medicine, Boston, MA, USA; 2Strategic Health Resources, La Canada, CA, USA; 3Greenwich Biosciences, Carls

  6. Slide 6: The Burden of Illness of Dravet Syndrome in the United States

    The Burden of Illness of Dravet Syndrome in the United States Michael Chez1 | Anup Patel2 | Susan E. Funk3 | Tyler J. Story4 Nancy L. Reaven3 1Sutter Medical Group, Sacramento, CA, USA; 2Nationwide Children’s Hospital, Columbus, OH, USA; 3Strategic Health Resources, La Cañada, CA, USA; 4Greenwich Bi

  7. Slide 7: Antiseizure Properties of CBD Attenuated in Absence of TRPV1 Receptors

    Antiseizure Properties of Cannabidiol (CBD) Are Attenuated in the Absence of Transient Receptor Potential Vanilloid 1 (TRPV1) Receptors Nicholas Jones | Colin Stott | Elizabeth Roberts | Royston Gray GW Research Ltd, Cambridge, UK SUMMARY • The dose-dependent CBD-mediated increase in seizure thresho

  8. Slide 8: A Role of GPR55 in the Antiepileptic Properties of Cannabidiol

    A Role of GPR55 in the Antiepileptic Properties of Cannabidiol Michael Bazelot1,2 | Evan C. Rosenberg3 | Royston Gray2 | Orrin Devinsky3 | Benjamin J. Whalley2 | Richard W. Tsien3 1University of Reading, Reading, UK; 2GW Research Ltd, Cambridge, UK; 3New York University, New York, NY, USA. SUMMARY •

  9. Slide 9: Human Metabolite 7-Hydroxy Cannabidiol Is Anticonvulsant in Mouse mEST Test

    Human Metabolite of Cannabidiol, 7-Hydroxy Cannabidiol, but Not 7-Carboxy Cannabidiol, Is Anticonvulsant in the Maximal Electroshock Seizure Threshold (mEST) Test in Mouse Benjamin J. Whalley | Colin Stott | Royston A. Gray | Nicholas A. Jones GW Research Ltd, Cambridge, UK SUMMARY • 7-hydroxy canna

  10. Slide 10: Cannabidiol Improves the Welfare and Survival of Dravet Syndrome Mice

    Cannabidiol Improves the Welfare and Survival of Dravet Syndrome Mice Pabitra H. Patra1,2 | Alister McNeish1 | Claire M. Williams2 | Benjamin J. Whalley1,3 | Michael Bazelot1,3 1School of Pharmacy, University of Reading, Reading, UK; 2School of Psychology & Clinical Language Sciences, University of

  11. Slide 11: Supplementary Table: Welfare Assessment for Dravet Syndrome Mice

    Supplementary Table for Cannabidiol Improves the Welfare and Survival of Dravet Syndrome Mice Welfare assessment sheet for neonatal mice; adapted from (Wolfensohn and Lloyd, 2007 and Ullman- Cullere and Foltz, 1999). Parameters Scores Appearance/Colour Normal (pink) 0 Pink/blue abdomen 1 Pink/pale e

  12. Slide 12: Cannabidiol Improves Seizures and Epilepsy Associated Co-Morbidities in Rats

    Cannabidiol Improves Seizures and Epilepsy Associated Co-Morbidities in Rats Pabitra H. Patra1,2 | Haramrit Sandhu1 | Michael Bazelot1,3 | Benjamin J. Whalley1,3 | Claire M. Williams2 | Alister McNeish1 1School of Pharmacy, University of Reading, Reading, UK; 2School of Psychology & Clinical Languag

  13. Slide 13: Pharmacokinetics and Safety of CBD in Hepatic or Renal Impairment

    Pharmacokinetics and Safety Evaluation of Cannabidiol (CBD) in Subjects with Hepatic or Renal Impairment: Results of Two Phase 1 Trials Bola Tayo1 | Graham Blakey2 | Gilmour Morrison1 | Kevan VanLandingham3 1GW Research Ltd, Cambridge, UK; 2consult2deliver, Nottingham, UK, 3Greenwich Biosciences, In

  14. Slide 14: Cannabidiol Doses Do Not Significantly Affect Corrected QT Interval

    Single Therapeutic and Supratherapeutic Doses of Cannabidiol Do Not Significantly Affect Heart Rate Corrected QT Interval Kevan VanLandingham, MD, PhD1 | Robert Kleiman, MD2 | Bola Tayo, MBBS3 | Graham Blakey, PhD4 | Gilmour Morrison3 1Greenwich Biosciences, Research Triangle Park, NC, USA; 2ERT Cli

  15. Slide 15: Assessment of the Abuse Potential of Cannabidiol in Recreational Polydrug Users

    Assessment of the Abuse Potential of Cannabidiol in Recreational Polydrug Users: A Randomized, Double-Blind, Controlled Trial Kenneth Sommerville1 | Tilden Etges2 | Isabella Szeto3 | Beatrice Setnik3 | Catherine Mills3 | Kerri Schoedel4 | Naama Levy-Cooperman4 | Edward Sellers5 1Greenwich Bioscience

  16. Slide 16: Drug-Drug Interaction with Cannabidiol and Clobazam in Phase 1 Trial

    Bidirectional Drug-Drug Interaction with Coadministration of Cannabidiol and Clobazam in a Phase 1 Healthy Volunteer Trial Kenneth Sommerville1 | Julie Crockett2 | Graham Blakey3 | Gilmour Morrison2 1Greenwich Biosciences, Carlsbad, CA, USA; 2GW Research Ltd, Cambridge, UK; 3consult2deliver, Notting

  17. Slide 17: Cannabidiol Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome

    Cannabidiol Significantly Reduces Drop Seizure Frequency in Lennox-Gastaut Syndrome: Efficacy and Safety Results from 2 Randomized, Controlled Trials SUMMARY In this pooled analysis of 2 randomized, controlled trials of add-on cannabidiol (CBD) treatment in patients with Lennox-Gastaut syndrome (LGS

  18. Slide 18: Cannabidiol Treatment Effect and Adverse Events by Time in LGS

    Cannabidiol Treatment Effect and Adverse Events by Time in Patients with Lennox- Gastaut Syndrome: Pooled Results from 2 Randomized, Controlled Trials SUMMARY In this pooled analysis of 2 randomized, controlled trials of add-on cannabidiol (CBD) treatment in patients with Lennox-Gastaut syndrome (LG

  19. Slide 19: Exposure-Response Analysis of Cannabidiol for Lennox-Gastaut Syndrome

    Exposure-Response Analysis of Cannabidiol (CBD) for the Treatment of Lennox-Gastaut Syndrome SUMMARY • This study assessed whether the efficacy and safety of CBD treatment in patients with Lennox-Gastaut syndrome (LGS) are related to the exposure of CBD or its active metabolite 7-OH-CBD. • Children

  20. Slide 20: Cannabidiol Responder Analysis in LGS On and Off Clobazam

    Cannabidiol Treatment Responder Analysis in Patients with Lennox-Gastaut Syndrome On and Off Clobazam SUMMARY • Add-on cannabidiol (CBD) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) resulted in clinically meaningful seizure reductions vs add-on placebo, regardless of concomita

  21. Slide 21: Long-Term Safety and Efficacy of Cannabidiol in Dravet Syndrome (GWPCARE5)

    Long-Term Safety and Efficacy of Cannabidiol Treatment in Dravet Syndrome: Results of an Open-Label Extension Trial (GWPCARE5) Orrin Devinksy1 | Rima Nabbout2 | Ian Miller3 | Linda Laux4 Marta Zolnowska5 | Stephen Wright6 | Claire Roberts6 1NYU Comprehensive Epilepsy Center, New York, NY, USA; 2Neck

  22. Slide 22: Long-Term Open-Label Cannabidiol Trial in Lennox-Gastaut Syndrome (GWPCARE5)

    Maintained Safety and Efficacy of Cannabidiol in a Long-Term Open-Label Trial in Patients with Lennox-Gastaut Syndrome (GWPCARE5) SUMMARY In this long-term extension safety and efficacy trial of add-on cannabidiol (CBD) in patients with Lennox-Gastaut syndrome (LGS) who rolled over from 2 randomized

  23. Slide 23: Long-Term Safety of Cannabidiol in Treatment-Resistant Epilepsies: EAP Results

    Long-Term Safety and Treatment Effect of Cannabidiol in Children and Adults with Treatment-Resistant Epilepsies (TRE): Expanded Access Program (EAP) Results SUMMARY • Since 2014, children and adults with severe TRE have been treated with cannabidiol (CBD) through an extensive EAP comprising individu

  24. Slide 24: Long-Term Cannabidiol in LGS or Dravet Syndrome: Expanded Access Program Results

    Long-Term Safety and Treatment Effect of Cannabidiol in Children and Adults with Treatment-Resistant Lennox-Gastaut Syndrome or Dravet Syndrome: Expanded Access Program (EAP) Results SUMMARY • Since 2014, children and adults with severe treatment-resistant epilepsy (TRE) have been treated with canna

GW Pharmaceuticals — Technical Presentation (December 2017) on 6ix